Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Alphamab Oncology ( (HK:9966) ) is now available.
Alphamab Oncology announced promising interim results from a Phase III clinical trial of KN026, a next-generation HER2-targeted therapy, in combination with chemotherapy for HER2+ gastric cancer patients. The trial demonstrated significant improvements in progression-free survival and overall survival compared to chemotherapy alone, with a manageable safety profile, positioning KN026 as a potential new treatment option for patients who have progressed on trastuzumab-based therapy.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a biopharmaceutical company focused on the development of innovative therapies for cancer treatment. The company specializes in creating next-generation HER2-targeted therapies, with a strong emphasis on global-level drug development and clinical trials.
Average Trading Volume: 4,088,798
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.35B
See more insights into 9966 stock on TipRanks’ Stock Analysis page.